Parodis et al1 | Oon et al2 |
1. SLEDAI-2K score≤4 with no activity in the renal descriptors (proteinuria, pyuria, haematuria and cellular casts), no pleurisy, no pericarditis and no fever. | 1. SLEDAI-2K score≤4 with no activity in major organ systems (renal, central nervous system, cardiopulmonary, vasculitis an fever) and no haemolytic anaemia or gastrointestinal activity. |
2. No new features of SLE activity, defined as no new moderate or severe flare according to the SELENA-SLEDAI Flare Index compared with baseline. | 2. No new features of lupus disease activity, defined as no new SELENA-SLEDAI item score>0 and no new BILAG activity compared with the previous assessment. |
3. SELENA-SLEDAI PGA score≤1 (scale: 0–3). | 3. SELENA-SLEDAI PGA score≤1 (scale: 0–3). |
4. Daily prednisone or prednisone equivalent dose≤7.5 mg. | 4. Current prednisone equivalent dose≤7.5 mg/day. |
5. Standard maintenance dosages of immunosuppressive drugs and approved biologic agents. |
All criteria had to be met for attainment of LLDAS.
.BILAG, British Isles Lupus Assessment Group; LLDAS, Lupus Low Disease Activity State;PGA, physician’s global assessment;SELENA, Safety of Estrogens in Lupus Erythematosus National Assessment;SLE, systemic lupus erythematosus;SLEDAI-2K, Systemic Lupus Erythematosus Disease Activity Index 2000.